Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | KDM4B | O94953 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3188444 | 0.98 | CA9 (0.34) | NR1I2KDM4BCHRM1TBXA2RADRA1A | |
| SCHEMBL3190887 | 0.77 | CA9 (0.33) | CA9 | |
| SCHEMBL3180645 | 0.68 | CA9 (0.43) | CA9 | |
| SCHEMBL8187039 | 0.65 | CA9 (0.41) | CA9 | |
| SCHEMBL9359924 | 0.65 | JAK2 (0.35) | NR1I2KDM4BCHRM1TBXA2RADRA1A | |
| SCHEMBL17350280 | 0.65 | CA9 (0.41) | CA9 | |
| SCHEMBL4949641 | 0.64 | CA9 (0.46) | CA9 | |
| SCHEMBL14620427 | 0.64 | CEL (0.33) | NR1I2KDM4BCHRM1TBXA2RADRA1A | |
| SCHEMBL10679447 | 0.63 | KMT2A (0.34) | NR1I2KDM4BCHRM1TBXA2RADRA1A | |
| SCHEMBL6944629 | 0.63 | DAO (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662957-B2 | Method for producing 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or salt thereof | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-02-16 | — | — | US | disclosed |
| US-20090318685-A1 | METHOD FOR PRODUCING 3,4-DIHYDRO-1,2,3-OXATHIAZIN-4-ONE-2,2-DIOXIDE COMPOUND OR SALT THEREOF | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-7408059-B2 | 6-methyl-3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide; cyclizing a beta-ketoamide-N-sulfonic acid with an acid anhydride | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2008-08-05 | — | — | US | disclosed |
| US-20050182255-A1 | Method for producing 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or salt thereof | DAICEL CHEMICAL INDUSTRIES, LTD. | 2005-08-18 | — | — | US | disclosed |
| EP-1564211-A1 | Method for producing 3,4-Dihydro-1,2,3-Oxathiazin-4-one-2,2-Dioxide compound or salt thereof | Daicel Chemical Industries, Ltd. (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182255-A1 | Method for producing 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or salt thereof | CA2, HAO2, SRD5A2 | NR1I2 1366/4885KDM4B 1154/4885CHRM1 1894/4885 |
| US-20090318685-A1 | METHOD FOR PRODUCING 3,4-DIHYDRO-1,2,3-OXATHIAZIN-4-ONE-2,2-DIOXIDE COMPOUND OR SALT THEREOF | CA2, HAO2, KYAT1 | NR1I2 2595/4885KDM4B 566/4885CHRM1 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.